š¬ Current Disease Focus:
Task Progress: 0%
š„ Active Problem Solvers
0
š Experts collaborating globally
ā” Current Task Assignment
š§¬ Genetic Analysis
š Matching experts to specific tasks
š Resource Allocation by Research Phase:
š Data Analysis
š§Ŗ Experimental Design
š¬ Clinical Trials
š Treatment Development
Purpose: To develop a real time national clinical database to support and ...
Status
Completed
Location
Multiple Locations
Start Date
2005-06
Trial ID
NCT00371774
Alefacept (AMEVIVEĀ®) is an immunosuppressive dimeric fusion protein. It was...
Status
Terminated
Location
Department of Stem Cell Transplantation & Cancer Immunotherapy
Start Date
2006-06
Trial ID
NCT00361413
Treatments Being Tested
This study will assess the safety, tolerability, and efficacy of Alefacept ...
Status
Completed
Location
Rush University Medical Center - Department of Dermatology
Start Date
2008-01
Trial ID
NCT00832585
Treatments Being Tested
The purpose of this research study is to see how well the medication Alefac...
Status
Completed
Location
Wake Forest University Health Sciences
Start Date
2008-05
Trial ID
NCT00655564
Treatments Being Tested
The purpose of this trial is to test whether a drug called alefacept will s...
Status
Terminated
Location
University of Arizona
Start Date
2011-03
Trial ID
NCT00965458
To evaluate the safety of treating subjects with up to 12 additional doses ...
Status
Completed
Location
Monheit Dermatology Associates
Start Date
2004-07
Trial ID
NCT00168753
Treatments Being Tested
A vaccine causes the immune system to produce antibodies (immune response) ...
Status
Completed
Location
Multiple Locations
Start Date
2007-07
Trial ID
NCT00493324
Treatments Being Tested
Subjects exposed to alefacept are to be enrolled. Subjects will be contacte...
Status
Terminated
Location
Total Skin and Beauty Dermatology Center
Start Date
2003-06
Trial ID
NCT00454701
Treatments Being Tested
This is an observational, exposure-registration and follow-up study, to be ...
Status
Terminated
Location
INC Research
Start Date
2003-12
Trial ID
NCT00342862
Treatments Being Tested